 Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir and Ledipasvir from Magicbuvir Plus 90400 mg Tablets Magic Pharma, Egypt Versus Harvoni 90400 mg Tablets Gilead Sciences, Canada in Healthy Human Volunteers Under Fed Condition. 